Liquidia (NASDAQ:LQDA) Director Paul Manning Sells 200,000 Shares

Liquidia Corporation (NASDAQ:LQDA) Director Paul Manning sold 200,000 shares of the business’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $63.91, for a total value of $12,782,000.00. Following the completion of the transaction, the director directly owned 716,311 shares of the company’s stock, valued at approximately $45,779,436.01. This trade represents a 21.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Liquidia Stock Performance

NASDAQ LQDA opened at $63.90 on Tuesday. Liquidia Corporation has a fifty-two week low of $11.85 and a fifty-two week high of $66.78. The stock has a market cap of $5.68 billion, a price-to-earnings ratio of 456.46 and a beta of 0.57. The business has a fifty day moving average of $47.32 and a 200-day moving average of $39.87. The company has a quick ratio of 2.03, a current ratio of 2.22 and a debt-to-equity ratio of 1.18.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings results on Monday, May 11th. The company reported $0.52 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.11. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The company had revenue of $132.87 million during the quarter, compared to analysts’ expectations of $119.44 million. Liquidia’s revenue for the quarter was up 4187.1% on a year-over-year basis. As a group, analysts predict that Liquidia Corporation will post 2.97 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Liquidia

Institutional investors have recently added to or reduced their stakes in the company. Northwestern Mutual Wealth Management Co. purchased a new stake in Liquidia during the fourth quarter valued at about $25,000. Covestor Ltd grew its position in Liquidia by 41.9% during the fourth quarter. Covestor Ltd now owns 1,216 shares of the company’s stock valued at $42,000 after acquiring an additional 359 shares during the period. Skandinaviska Enskilda Banken AB publ purchased a new stake in Liquidia during the third quarter valued at about $30,000. FNY Investment Advisers LLC purchased a new stake in Liquidia during the third quarter valued at about $34,000. Finally, NewEdge Advisors LLC purchased a new stake in shares of Liquidia in the second quarter worth about $25,000. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. Wells Fargo & Company boosted their price target on Liquidia from $51.00 to $62.00 and gave the stock an “overweight” rating in a report on Tuesday, May 12th. Needham & Company LLC upped their target price on Liquidia from $54.00 to $70.00 and gave the company a “buy” rating in a research note on Monday, May 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Liquidia in a research note on Tuesday, April 21st. Raymond James Financial reiterated a “strong-buy” rating and issued a $68.00 target price on shares of Liquidia in a research note on Thursday. Finally, Zacks Research upgraded Liquidia from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 5th. Three research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have given a Sell rating to the company. According to MarketBeat.com, Liquidia currently has an average rating of “Moderate Buy” and a consensus price target of $55.63.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).